Compare Amylx Pharmaceuticals Inc (AMLX) vs Raytheon Technologies Corp (RTX) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

RTX trades at $195.93, up 0.37% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026 EPS of $1.78 versus $1.51 expected, highlight robust operational performance. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.03%. The company secured a $515 million U.S. Navy contract for SPY-6 radars (PRNewsWire, 2026-06-03), reinforcing its defense segment strength.

The outlook is positive, driven by defense contract wins and commercial aerospace recovery, but risks include debt levels and geopolitical uncertainties. With a consensus price target of $213.00 (18 buy, 8 hold, 0 sell), the stock offers potential upside, though valuation multiples like a P/E of 36.76 warrant monitoring amid interest rate sensitivity.